• Drug Development for all major focus therapeutic areas including Oncology, Immunology, CV, Diabetes and metabolic diseases, Urology etc. • BusStim (Business Stimulus Consultants) works on assets that are usually brought in through partnership in the late-discovery/Pre-Clinical stage and then developed to Phase II/IIb clinical for an eventual Licensing to other Pharma. Phase III clinical and market strategy are also offered as part of the out-licensing package. Translational Research… Show more • Drug Development for all major focus therapeutic areas including Oncology, Immunology, CV, Diabetes and metabolic diseases, Urology etc. • BusStim (Business Stimulus Consultants) works on assets that are usually brought in through partnership in the late-discovery/Pre-Clinical stage and then developed to Phase II/IIb clinical for an eventual Licensing to other Pharma. Phase III clinical and market strategy are also offered as part of the out-licensing package. Translational Research, novel trial designs and other tools are used to drive drug development as well as to shorten the development timelines. Funds are raised for partnered asset from Investment Bank/Venture Funds/Institutional Investors/ Investment community to fund development activities.• Managing team of over 40 top level consultants ranging in experience from the late discovery to market. Managing also partnership with CRO’s, Biotechs and other groups who form a part of the BusStim network.• Licensing and Partnerships including comprehensive due-diligence which lie as the core of the BusStim’s Risk-Sharing drug development model. The goal being to take on assets for which there is an acute market/licensing need and also where novel strategies to shorten development time can be applied.• Overall Business Strategy from the near horizon operational strategy to long term business strategy.• Financial valuation of a large number of Assets and Firms using the latest tools and methods. Both buy and sell side valuations are carried out based on the firm or asset status including valuation of some firms with complicated structure and IP scenarios.• Creating Budgets and support for Budgetary controls as needed to keep down cost of development typically below industry norms.• Created a constantly evolving out-licensing product package which includes risk analysis, competition analysis, market/niche analysis and product positioning.Web: http://www.busstim.com/about-busstim/our-management-team/ Show less

General Management, Strategy, In and Out-licensing, Budgets, Startups, Alliance management, Investor relationship, Financial valuation, Overall Project/Program Management, Projections/Forecasting and Team building • Positioned and differentiated the company from the usual contract research spectrum by establishing the company as a center for excellence with capabilities in Drug Development (Pre-clinical to clinical) for Pharmaceutical/Biotech clients. Capabilities in the Agrochemical… Show more General Management, Strategy, In and Out-licensing, Budgets, Startups, Alliance management, Investor relationship, Financial valuation, Overall Project/Program Management, Projections/Forecasting and Team building • Positioned and differentiated the company from the usual contract research spectrum by establishing the company as a center for excellence with capabilities in Drug Development (Pre-clinical to clinical) for Pharmaceutical/Biotech clients. Capabilities in the Agrochemical have been augmented by establishing one of the few radio-tracer study facilities in the country.• Implemented a multi-year strategic plan, with the company turning operationally profitable within 12 months and an expected CAGR of greater than 100% for the first 4 years.• Set up a lean and nimble operational team for projects, with the ability to bid for projects which would normally be off-shored. A multi-year project was signed with a major international client due to this initiative in the Agrochemical area.• Created a strategic alliance in the drug development area with an agency agreement established with a Pharma/Biotech company for developing their Rx oncology drug. Negotiation is at an advanced stage with an Investment Banking group for developing this drug via establishment of a syndicate.• Established a co-development agreement with a startup company to develop testing strips for toxic metals and organics in food, cosmetics and common household surfaces. These strips are planned for both point of use and point of sale application and prototypes are being worked on. Technology evaluated using the DCF approach and real option approach.Web: http://symbioticresearch.net/ka_kumar.html Show less

Project/Program management and Drug development including selection and guiding drug candidates through the preclinical stages as well as the clinical phases. Managed iv and oral oncology agents from the pre-clinical to early clinical stages. Managed the out-licensing activities of drugs on behalf of Taxolog. Directed and managed a Drug Discovery group successful in the areas of AntiMetabolites (Taxanes) in Oncology and Rheumatoid Arthritis.

Managed the Acros process development group for Fisher. Transferred the technology developed, to the Fisher pilot plant and production facility in Europe. Involved from the technological angle into the activities/business strategy of Fisher in the areas of pharmaceutics and bio-technology. Managed IP transfer and utilization from the acqusition of the Kodak Chemiclas business through Janssen.